# Champions Oncology, Inc.: Form 10-Q for the period ended Jul 31, 2015

- Company: [Champions Oncology, Inc.](/companies/csbr.md) (CIK 771856)
- Form: 10-Q
- Filed: 2015-09-11
- Accepted by EDGAR: Sep 11, 2015, 16:02 ET
- Period: 2015-07-31
- Accession: 0001144204-15-054634
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/771856/000114420415054634/v419058_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/771856/000114420415054634/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2015-07-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2015-05-01 to 2015-07-31 | $1.1m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2015-05-01 to 2015-07-31 | −$2.9m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2015-05-01 to 2015-07-31 | $6.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2015-05-01 to 2015-07-31 | −$2.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2015-05-01 to 2015-07-31 | −$0.33 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2015-05-01 to 2015-07-31 | −$0.33 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2015-05-01 to 2015-07-31 | 8,702,237 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Capital expenditure | 3 months, 2015-05-01 to 2015-07-31 | $29.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2015-07-31 | $6.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2015-07-31 | $8.6m | us-gaap:AssetsCurrent |
| Total assets | at 2015-07-31 | $9.8m | us-gaap:Assets |
| Current liabilities | at 2015-07-31 | $3.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2015-07-31 | $3.9m | us-gaap:Liabilities |
| Shareholders' equity | at 2015-07-31 | $5.9m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 11,658 characters.

*The following discussion of our historical results of operations and our liquidity and capital resources should be read in conjunction with the condensed consolidated financial statements and related notes that appear elsewhere in this report and our most recent annual report for the year ended April 30, 2015, as filed on Form 10-K.*

### Forward-Looking Statements

This Quarterly Report on Form 10-Q, including Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations, contains certain “forward-looking statements,” which include information relating to future events, future financial performance, strategies, expectations, competitive environment, regulation, and availability of resources. These forward-looking statements include, without limitation, statements regarding: proposed new programs; expectations that regulatory developments or other matters will not have a material adverse effect on our financial position, results of operations, or liquidity; statements concerning projections, predictions, expectations, estimates, or forecasts as to our business, financial and operational results, and future economic performance; and statements of management’s goals and objectives and other similar expressions concerning matters that are not historical facts. Words such as “may,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar expressions, as well as statements in future tense, identify forward-looking statements.

Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time those statements are made or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.

Forward-looking statements speak only as of the date the statements are made. Factors that could cause actual results to differ from those discussed in the forward-looking statements include, but are not limited to, those described in “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended April 30, 2015, as updated in our subsequent reports filed with the SEC, including any updates found in Part II, Item 1A of this or other reports on Form 10-Q. You should not put undue reliance on any forward-looking statements. We assume no obligation to update forward-looking statements to reflect actual results, changes in assumptions, or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. If we do update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

### Overview and Recent Developments

Champions Oncology, Inc. is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The Company’s TumorGraft Technology Platform is a novel approach to personalizing cancer care, based upon the implantation of human tumors in immune-deficient mice. The Company uses this technology, in conjunction with related products, to offer solutions for two customer groups:

- Our Personalized Oncology Solutions, or POS, business, which provides services to physicians and patients looking for information to help guide the development of personalized treatment plans.
- Our Translational Oncology Solutions, or TOS, business, which provides services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development that will lower costs and increase the speed of developing new drugs, as well as increase the adoption of existing drugs.

We plan to continue our efforts to expand our TumorGraft Technology Platform in order to expand our POS and TOS programs.

### Operating Results

The following table summarizes our operating results for the periods presented below (dollars in thousands):

| Operating revenue: | For the Three Months Ended July 31, 2015 | % of Revenue | 2014 | % of% Revenue | Change |
| --- | ---: | ---: | ---: | ---: | ---: |
| Personalized oncology solutions | $485 | 17.2% | $341 | 17.8% | 42.2% |
| Translational oncology solutions | 2,337 | 82.8 | 1,571 | 82.2 | 48.8 |
| Total operating revenue | 2,822 | 100.0 | 1,912 | 100.0 | 47.6 |
| **Costs and operating expenses:** |  |  |  |  |  |
| Cost of personalized oncology solutions | 661 | 23.4 | 757 | 39.6 | (12.7) |
| Cost of translational oncology solutions | 1,612 | 57.1 | 965 | 50.5 | 67.0 |
| Research and development | 1,100 | 39.0 | 1,423 | 74.4 | (22.7) |
| Sales and marketing | 1,029 | 36.5 | 1,034 | 54.1 | (0.5) |
| General and administrative | 1,317 | 46.7 | 1,462 | 76.5 | (9.9) |
| Total costs and operating expenses | 5,719 | 202.7 | 5,641 | 295.0 | 1.4 |
| Operating loss | $(2,897) | (102.7)% | $(3,729) | (195.0)% | (22.3) |

### Operating Revenues

Operating revenues were $2.8 million and $1.9 million for the three months ended July 31, 2015 and 2014, respectively, an increase of $892,000 or 46.7%.

POS revenues were $485,000 and $341,000 for the three months ended July 31, 2015 and 2014, respectively, an increase of $144,000, or 42.2%. Core revenue from its TumorGraft platform decreased $16,000 or (4.9%). This decrease is due to a 21.6% decline in implant revenue offset by a 6.3% increase in panel revenue. Non-core revenue increased $160,000.

TOS revenues were $2.3 million and $1.6 million for the three months ended July 31, 2015 and 2014, respectively, an increase of $766,000, or (48.8%). The increase is due to increased bookings in prior quarters due to the expansion of the TOS sales force and growth of the platform.

### Cost of Personalized Oncology Solutions

Cost of POS for the three months ended July 31, 2015 and 2014 was $661,000 and $757,000, respectively, a decrease of $96,000, or (12.7%). For the three months ended July 31, 2015 and 2014, gross margins for POS were (36.3%) and (122%), respectively. The improvement in gross margin is attributed to the increase in higher margin, non-core revenue and cost reductions in the core business.

### Cost of Translational Oncology Solutions

Cost of TOS for the three months ended July 31, 2015 and 2014 was $1.6 million and $965,000, respectively, an increase of $681,000, or 67%. For the three months ended July 31, 2015 and 2014, gross margins for TOS were 31% and 38.6%, respectively.

### Research and Development

Research and development expenses for the three months ended July 31, 2015 and 2014 was $1.1 million and $1.4 million, respectively, a decrease of $323,000, or (22.7%). The decrease is due to lower one-time expenses in genomic characterization of our TumorBank.

### Sales and Marketing

Sales and marketing expenses for both the three months ended July 31, 2015 and 2014 were $1.0 million, respectively.

### General and Administrative

General and administrative expenses for the three months ended July 31, 2015 and 2014 were $1.3 million and $1.46 million, respectively, a decrease of $146,000, or (9.9%). The decline is mainly due to a decrease in stock based compensation expense of $105,000.

### Other Income (Expense)

Other income (expense) for the three months ended July 31, 2015 and 2014 was ($10,000) and $186,000, a decrease in income of $196,000. The change is mainly due to $155,000 gain on fair value of warrants that were accounted for as liabilities in Q1 2015 which have been reclassified into equity. See the Company’s annual form 10K, footnote 7, filed on July 29, 2015 for further discussion.

### Inflation

Inflation does not have a meaningful impact on the results of our operations.

### Liquidity and Capital Resources

Our liquidity needs have typically arisen from the funding of our research and development programs and the launch of new products, working capital requirements, and other strategic initiatives. In the past, we have met these cash requirements through our sales of products and services, cash and cash equivalents, working capital management, and proceeds from certain private placements of our securities. As of July 31, 2015, we had positive working capital of $4.8 million and cash and cash equivalents on hand of $6.8 million. We believe that our cash and cash equivalents on hand at July 31, 2015 are adequate to fund our operations through at least May 31, 2016. However, in order for us to continue as a going concern beyond this point, we may need to obtain capital from external sources. If we are unable to obtain additional financing, we may be required to reduce the scope of, or delay or eliminate, some of our research and development and other activities, which could harm our financial condition and operating results. Financing may not be available on acceptable terms or at all, and our failure to raise capital when needed could negatively impact our growth plans and our financial condition and results of operations. Additional equity financing may be dilutive to the holders of our common stock and debt financing, if available, may involve significant cash payment obligations and covenants and/or financial ratios that restrict our ability to operate our business.

### Cash Flows

The following discussion relates to the major components of our cash flows:

#### Cash Flows from Operating Activities

Net cash used in operating activities was $2.6 million and $2.8 million for the three months ended July 31, 2015 and 2014, respectively, a decrease of $200,000.

#### Cash Flows from Investing Activities

Net cash used in investing activities was $29,000 and $33,000 for the three months ended July 31, 2015 and 2014, respectively. These cash flows primarily relate to the purchase of property and equipment.

#### Cash Flows from Financing Activities

Net cash used in financing activities was $25,000 and nil for the three months ended July 31, 2015 and 2014, respectively. These cash flows relate to issuance costs related to 2015 private placement and capital lease payments.

### Critical Accounting Estimates and Policies

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to apply methodologies and make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates of the Company include, among other things, accounts receivable realization, revenue recognition (replacement of licensed tumors), valuation allowance for deferred tax assets, valuation of goodwill, and stock compensation and warrant assumptions. Actual results could differ from those estimates. The Company’s critical accounting policies are summarized in the Company’s Annual Report on Form 10-K, filed with the SEC on July 29, 2015.

### Off-Balance Sheet Financing

We have no off-balance sheet debt or similar obligations. We have no transactions or obligations with related parties that are not disclosed, consolidated into or reflected in our reported results of operations or financial position. We do not guarantee any third-party debt.

## Controls and procedures

As filed, 1,676 characters.

### Evaluation of Disclosure Controls and Procedures

It is management’s responsibility to establish and maintain “disclosure controls and procedures” as such term is defined in Rule 13a-15 under the Securities Exchange Act of 1934. Our management, with the participation of our Chief Executive Officer and our Vice President, Finance, have reviewed and evaluated the effectiveness of our disclosure controls and procedures as of a date within ninety (90) days of the filing date of this Form 10-Q quarterly report. Based on that evaluation, our management, including our Chief Executive Officer and our Vice President, Finance, have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Form 10-Q at the reasonable assurance level in ensuring that information required to be disclosed in the reports that we file or submit under the Securities Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and is accumulated and communicated to management, including our Chief Executive Officer and our Vice President, Finance, as appropriate, to allow timely decisions regarding required disclosure.

### Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 2,309 characters.

**We may not be able to meet our cash requirements beyond May 31, 2016 without obtaining additional capital from external sources, and if we are unable to do so, we may not be able to continue as a going concern.**

As of July 31, 2015, we had working capital of $4.8 million and cash and cash equivalents of $6.8 million. We believe that our cash and cash equivalents on hand at July 31, 2015 are adequate to fund our operations through at least May 31, 2016. However, in order for us to continue as a going concern beyond this point, we may need to obtain capital from external sources.

We have generated net losses for our past recent history. For the years ended April 30, 2015 and 2014, the Company had a net loss of approximately $13.1 million and $7.4 million, respectively, and for the three months ended July 31, 2015, we had a net loss of $2.9 million. We may not be able to continue as a going concern without additional financing. Even if we do raise sufficient capital to support our operating expenses beyond May 31, 2016, there can be no assurances that the proceeds raised will be sufficient to enable our business to a level where it will generate profits from operations. Currently, the Company derives revenue from POS products and TOS products, while pursuing efforts to further develop bioinformatics from its TumorBank and its TumorGraft Technology Platform. In addition, we are building our sales and marketing operations to grow our TOS and POS products. Accordingly, we expect to generate operating losses in the future until such time as we are able to generate significantly more revenue.

If we are unable to obtain additional financing, we may be required to reduce the scope of, or delay or eliminate, some of our research and development and other activities, which could harm our financial condition and operating results. Financing may not be available on acceptable terms or at all, and our failure to raise capital when needed could negatively impact our growth plans and our financial condition and results of operations. Additional equity financing may be dilutive to the holders of our common stock and debt financing, if available, may involve significant cash payment obligations and covenants and/or financial ratios that restrict our ability to operate our business.

Filed Sep 11, 2015.
Source: SEC EDGAR, the filing index for accession 0001144204-15-054634. Last ingested by Listed: Nov 10, 2026, 03:33 ET. No prices; not investment advice.
